Skip to main content

Tanezumab in Osteoarthritis: Data Presented at OARSI

Pooled analyses of the tanezumab (a nerve growth factor inhibitor) phase 3 studies was presented at the 2015 Osteoarthritis Research Society International (OARSI) World Congress. Safety and efficacy data from 2,979 patients with moderate-to-severe hip or knee OA (25% had severe OA) is detailed in this report. Adverse events and withdrawals were equal to comparators but more than placebo. Neuropathic sensations were more common on the biologic (5.8%) compared to placebo (1.7%).

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject